OPRK1 and plasma cell myeloma: U50,488, a kappa-opioid receptor agonist, favored apoptosis in human multiple-myeloma cells expressing mu- and kappa-opioid receptors; but the antiproliferative effect was not mediated by kappa receptors [235].